 |
Galecto Biotech
Last updated: July 23, 2024
Hans Schambye - Co-Founder & CEO
Denmark | Funding: $160.4M (+)
Website: https://galecto.com
Galecto develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform.
Website: https://galecto.com
Galecto develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform.
